Strong Signals of Adverse Events in Tyrosine Kinase Inhibitor Therapy for Liver Cancer Treatment
{{output}}
Background: This study was to identify strong adverse event (AE) signals associated with four tyrosine kinase inhibitors (TKIs) (sorafenib, regorafenib, lenvatinib, and cabozantinib), and compare these signals with regulatory dru... ...
